SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-074628
Filing Date
2024-03-22
Accepted
2024-03-22 08:33:30
Documents
15
Period of Report
2024-03-21
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d796451d8k.htm   iXBRL 8-K 32038
2 EX-3.2 d796451dex32.htm EX-3.2 5648
3 EX-10.1 d796451dex101.htm EX-10.1 43995
  Complete submission text file 0001193125-24-074628.txt   224854

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cogt-20240321.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20240321_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20240321_pre.xml EX-101.PRE 11711
18 EXTRACTED XBRL INSTANCE DOCUMENT d796451d8k_htm.xml XML 3832
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 24773194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)